S&P 500
(0.12%) 5 303.27 points
Dow Jones
(0.34%) 40 004 points
Nasdaq
(-0.07%) 16 686 points
Oil
(0.97%) $80.00
Gas
(5.73%) $2.64
Gold
(1.44%) $2 419.80
Silver
(6.36%) $31.78
Platinum
(2.18%) $1 094.70
USD/EUR
(-0.02%) $0.920
USD/NOK
(-0.18%) $10.68
USD/GBP
(-0.27%) $0.787
USD/RUB
(0.19%) $91.05

Actualizaciones en tiempo real para ProKidney Corp. [PROK]

Bolsa: NASDAQ Capital Market Sector: Healthcare Industria: Biotechnology
BUY
100.00%
return 5.98%
SELL
0.00%
return 5.90%
Última actualización17 may 2024 @ 16:00

6.99% $ 4.06

COMPRAR 138193 min ago

@ $1.280

Emitido: 13 feb 2024 @ 09:30


Retorno: 216.80%


Señal anterior: feb 12 - 14:52


Señal anterior: Vender


Retorno: -3.76 %

Live Chart Being Loaded With Signals

Commentary (17 may 2024 @ 16:00):

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract...

Stats
Volumen de hoy 546 394
Volumen promedio 774 563
Capitalización de mercado 939.54M
EPS $0 ( 2024-05-09 )
Próxima fecha de ganancias ( $-0.220 ) 2024-08-08
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -7.11
ATR14 $0.00700 (0.17%)
Insider Trading
Date Person Action Amount type
2024-03-25 Control Empresarial De Capitales S.a. De C.v. Buy 30 000 Class A Ordinary Shares (as defined in Exhibit 99.1 hereto)
2024-03-22 Control Empresarial De Capitales S.a. De C.v. Buy 14 000 Class A Ordinary Shares (as defined in Exhibit 99.1 hereto)
2024-03-20 Control Empresarial De Capitales S.a. De C.v. Buy 33 000 Class A Ordinary Shares (as defined in Exhibit 99.1 hereto)
2024-03-14 Control Empresarial De Capitales S.a. De C.v. Buy 50 000 Class A Ordinary Shares (as defined in Exhibit 99.1 hereto)
2024-03-13 Control Empresarial De Capitales S.a. De C.v. Buy 50 000 Class A Ordinary Shares (as defined in Exhibit 99.1 hereto)
INSIDER POWER
-30.35
Last 98 transactions
Buy: 21 980 380 | Sell: 30 162 499

Volumen Correlación

Largo: 0.28 (neutral)
Corto: 0.36 (neutral)
Signal:(69.74) Neutral

ProKidney Corp. Correlación

10 Correlaciones Más Positivas
10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ProKidney Corp. Correlación - Moneda/Commodity

The country flag 0.05
( neutral )
The country flag 0.48
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag -0.09
( neutral )

ProKidney Corp. Finanzas

Annual 2023
Ingresos: $0
Beneficio Bruto: $-3.17M (0.00 %)
EPS: $-0.570
FY 2023
Ingresos: $0
Beneficio Bruto: $-3.17M (0.00 %)
EPS: $-0.570
FY 2022
Ingresos: $0
Beneficio Bruto: $-3.04M (0.00 %)
EPS: $-2.41
FY 2021
Ingresos: $0.00
Beneficio Bruto: $0.00 (0.00 %)
EPS: $-0.296

Financial Reports:

No articles found.

ProKidney Corp. Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

ProKidney Corp.

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Acerca de Señales en Vivo

Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.

Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico